Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study.

Alborelli I, Generali D, Jermann P, Cappelletti MR, Ferrero G, Scaggiante B, Bortul M, Zanconati F, Nicolet S, Haegele J, Bubendorf L, Aceto N, Scaltriti M, Mucci G, Quagliata L, Novelli G.

Cell Death Dis. 2019 Jul 11;10(7):534. doi: 10.1038/s41419-019-1770-3.

2.

Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials.

Corona SP, Roviello G, Strina C, Milani M, Madaro S, Zanoni D, Allevi G, Aguggini S, Cappelletti MR, Francaviglia M, Azzini C, Cocconi A, Sirico M, Bortul M, Zanconati F, Giudici F, Rosellini P, Meani F, Pagani O, Generali D.

Breast. 2019 Aug;46:19-24. doi: 10.1016/j.breast.2019.04.004. Epub 2019 Apr 25.

PMID:
31051411
3.

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper.

Cristofanilli M, Pierga JY, Reuben J, Rademaker A, Davis AA, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Giuliano M, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Cabel L, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Generali D, Cappelletti MR, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Darrigues L, Reis-Filho JS, Gerratana L, Michiels S, Bidard FC, Pantel K.

Crit Rev Oncol Hematol. 2019 Feb;134:39-45. doi: 10.1016/j.critrevonc.2018.12.004. Epub 2018 Dec 19. Review.

PMID:
30771872
4.

Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit.

Triulzi T, Regondi V, De Cecco L, Cappelletti MR, Di Modica M, Paolini B, Lollini PL, Di Cosimo S, Sfondrini L, Generali D, Tagliabue E.

Br J Cancer. 2018 Dec;119(12):1487-1494. doi: 10.1038/s41416-018-0318-0. Epub 2018 Nov 27.

5.

Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts.

Guffanti F, Fratelli M, Ganzinelli M, Bolis M, Ricci F, Bizzaro F, Chilà R, Sina FP, Fruscio R, Lupia M, Cavallaro U, Cappelletti MR, Generali D, Giavazzi R, Damia G.

Oncotarget. 2018 May 15;9(37):24707-24717. doi: 10.18632/oncotarget.25185. eCollection 2018 May 15.

6.

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K.

J Natl Cancer Inst. 2018 Jun 1;110(6):560-567. doi: 10.1093/jnci/djy018.

PMID:
29659933
7.

Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer.

Milani M, Venturini S, Bonardi S, Allevi G, Strina C, Cappelletti MR, Corona SP, Aguggini S, Bottini A, Berruti A, Jubb A, Campo L, Harris AL, Gatter K, Fox SB, Generali D, Roviello G.

Oncotarget. 2017 Aug 14;8(45):78870-78881. doi: 10.18632/oncotarget.20239. eCollection 2017 Oct 3.

8.

Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer.

Roviello G, Corona SP, Bonetta A, Cappelletti MR, Generali D.

Onco Targets Ther. 2017 Jul 31;10:3811-3815. doi: 10.2147/OTT.S143020. eCollection 2017.

9.

Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma.

Bonetta A, Roviello G, Generali D, Zanotti L, Cappelletti MR, Pacifico C, Di Pierro F.

Res Rep Urol. 2017 Apr 26;9:65-69. doi: 10.2147/RRU.S133538. eCollection 2017.

10.

Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?

Roviello G, Zanotti L, Cappelletti MR, Gobbi A, Dester M, Paganini G, Pacifico C, Generali D, Roudi R.

Clin Exp Med. 2018 Feb;18(1):15-20. doi: 10.1007/s10238-017-0460-7. Epub 2017 Apr 8. Review.

PMID:
28391544
11.

Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility.

Ravelli A, Roviello G, Cretella D, Cavazzoni A, Biondi A, Cappelletti MR, Zanotti L, Ferrero G, Ungari M, Zanconati F, Bottini A, Alfieri R, Petronini PG, Generali D.

Tumour Biol. 2017 Apr;39(4):1010428317695023. doi: 10.1177/1010428317695023. Review.

PMID:
28378631
12.

CDK4/6 inhibitors in HER2-positive breast cancer.

Corona SP, Ravelli A, Cretella D, Cappelletti MR, Zanotti L, Dester M, Gobbi A, Petronini PG, Generali D.

Crit Rev Oncol Hematol. 2017 Apr;112:208-214. doi: 10.1016/j.critrevonc.2017.02.022. Epub 2017 Feb 24. Review.

PMID:
28325261
13.

New molecular therapies in patients with advanced Hepatocellular Cancer in second line of treatment: Is a real defeat?: Results from a literature based meta-analysis of randomized trials.

Roviello G, Zanotti L, Cappelletti MR, Gobbi A, Borsella G, Pacifico C, Multari AG, Generali D.

Crit Rev Oncol Hematol. 2016 Dec;108:62-68. doi: 10.1016/j.critrevonc.2016.10.015. Epub 2016 Oct 29. Review.

PMID:
27931841
14.

Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials.

Roviello G, Cappelletti MR, Zanotti L, Gobbi A, Senti C, Bottini A, Ravelli A, Bonetta A, Paganini G, Generali D.

Medicine (Baltimore). 2016 Oct;95(43):e4636. Review.

15.

Low-Dose Oral Ethinylestradiol With Concomitant Low-Dose Acetylsalicylic Acid for Advanced Castrate-Resistant Prostate Cancer.

Roviello G, Zanotti L, Gobbi A, Dester M, Generali D, Pacifico C, Cappelletti MR, Bonetta A.

Clin Genitourin Cancer. 2017 Jun;15(3):371-375. doi: 10.1016/j.clgc.2016.08.024. Epub 2016 Sep 8.

PMID:
27692697
16.

Apatinib for the treatment of gastric cancer.

Roviello G, Ravelli A, Fiaschi AI, Cappelletti MR, Gobbi A, Senti C, Zanotti L, Polom K, Reynolds AR, Fox SB, Generali D.

Expert Rev Gastroenterol Hepatol. 2016 Aug;10(8):887-92. doi: 10.1080/17474124.2016.1209407. Epub 2016 Jul 15. Review.

PMID:
27376400
17.

No Advantage in Survival With Targeted Therapies as Maintenance in Patients With Limited and Extensive-Stage Small Cell Lung Cancer: A Literature-Based Meta-Analysis of Randomized Trials.

Roviello G, Zanotti L, Cappelletti MR, Gobbi A, Senti C, Bottini A, Generali D.

Clin Lung Cancer. 2016 Sep;17(5):334-340. doi: 10.1016/j.cllc.2016.05.008. Epub 2016 Jun 2. Review.

PMID:
27346522
18.

A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial.

Roviello G, Milani M, Gobbi A, Dester M, Cappelletti MR, Allevi G, Aguggini S, Ravelli A, Gussago F, Cocconi A, Zanotti L, Senti C, Strina C, Bottini A, Generali D.

Future Oncol. 2016 Oct;12(19):2189-93. doi: 10.2217/fon-2016-0116. Epub 2016 Jun 21.

PMID:
27324108
19.

Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials.

Roviello G, Sigala S, Sandhu S, Bonetta A, Cappelletti MR, Zanotti L, Bottini A, Sternberg CN, Fox SB, Generali D.

Eur J Cancer. 2016 Jul;61:111-21. doi: 10.1016/j.ejca.2016.04.002. Epub 2016 May 7. Review.

PMID:
27162152
20.

Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials.

Roviello G, Sigala S, Danesi R, Re MD, Bonetta A, Cappelletti MR, Zanotti L, Bottini A, Generali D.

Crit Rev Oncol Hematol. 2016 May;101:12-20. doi: 10.1016/j.critrevonc.2016.02.013. Epub 2016 Feb 27. Review.

PMID:
26971992
21.

A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast Cancers.

Roviello G, Milani M, Gobbi A, Cappelletti MR, Zanotti L, Senti C, Bottini A, Strina C, Sigala S, Generali D.

Clin Breast Cancer. 2016 Jun;16(3):e57-9. doi: 10.1016/j.clbc.2016.02.012. Epub 2016 Feb 11.

PMID:
26943987
22.

Breast cancer circulating biomarkers: advantages, drawbacks, and new insights.

Ravelli A, Reuben JM, Lanza F, Anfossi S, Cappelletti MR, Zanotti L, Gobbi A, Senti C, Brambilla P, Milani M, Spada D, Pedrazzoli P, Martino M, Bottini A, Generali D; Solid Tumor Working Party of European Blood and Marrow Transplantation Society (EBMT).

Tumour Biol. 2015 Sep;36(9):6653-65. doi: 10.1007/s13277-015-3944-7. Epub 2015 Aug 26. Review.

PMID:
26307395
23.

Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer?

Cappelletti MR, Gnetti L, Santini D, Spada D, Fox SB, Generali D.

Oncoscience. 2015 Jun 5;2(6):567-9. eCollection 2015. No abstract available.

24.

International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).

Amoroso V, Generali D, Buchholz T, Cristofanilli M, Pedersini R, Curigliano G, Daidone MG, Di Cosimo S, Dowsett M, Fox S, Harris AL, Makris A, Vassalli L, Ravelli A, Cappelletti MR, Hatzis C, Hudis CA, Pedrazzoli P, Sapino A, Semiglazov V, Von Minckwitz G, Simoncini EL, Jacobs MA, Barry P, Kühn T, Darby S, Hermelink K, Symmans F, Gennari A, Schiavon G, Dogliotti L, Berruti A, Bottini A.

J Natl Cancer Inst Monogr. 2015 May;2015(51):90-6. doi: 10.1093/jncimonographs/lgv023.

25.

RNA Disruption and Drug Response in Breast Cancer Primary Systemic Therapy.

Pritzker K, Pritzker L, Generali D, Bottini A, Cappelletti MR, Guo B, Parissenti A, Trudeau M.

J Natl Cancer Inst Monogr. 2015 May;2015(51):76-80. doi: 10.1093/jncimonographs/lgv015.

PMID:
26063893
26.

Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1α and Relation to Clinical Response.

Generali D, Berruti A, Cappelletti MR, Zanotti L, Brugnoli G, Forti M, Bedussi F, Vailati ME, Milani M, Strina C, Ardine M, Aguggini S, Allevi G, Ferrero G, Bertoni R, Bottini A, Harris AL, Fox SB.

J Natl Cancer Inst Monogr. 2015 May;2015(51):64-6. doi: 10.1093/jncimonographs/lgv018.

PMID:
26063890
27.

Neoadjuvant Treatment Approach: The Rosetta Stone for Breast Cancer?

Generali D, Ardine M, Strina C, Milani M, Cappelletti MR, Zanotti L, Forti M, Bedussi F, Martinotti M, Amoroso V, Sigala S, Simoncini E, Berruti A, Bottini A.

J Natl Cancer Inst Monogr. 2015 May;2015(51):32-5. doi: 10.1093/jncimonographs/lgv019.

PMID:
26063883
28.

Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity.

Ravelli A, Reuben JM, Lanza F, Anfossi S, Cappelletti MR, Zanotti L, Gobbi A, Milani M, Spada D, Pedrazzoli P, Martino M, Bottini A, Generali D; Solid Tumor Working Party of the European Blood and Marrow Transplantation Society (EBMT).

Expert Rev Anticancer Ther. 2015 Jun;15(6):689-702. doi: 10.1586/14737140.2015.1042864. Epub 2015 Apr 30. Review.

PMID:
25927868
29.

Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use.

Zanotti L, Bottini A, Rossi C, Generali D, Cappelletti MR.

Tumour Biol. 2014 Sep;35(9):8461-70. doi: 10.1007/s13277-014-2366-2. Epub 2014 Jul 23. Review.

PMID:
25048969
30.

Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy.

Koukourakis MI, Giatromanolaki A, Bottini A, Cappelletti MR, Zanotti L, Allevi G, Strina C, Ardine M, Milani M, Brugnoli G, Martinotti M, Ferrero G, Bertoni R, Ferrozzi F, Harris AL, Generali D.

Br J Cancer. 2014 Apr 29;110(9):2209-16. doi: 10.1038/bjc.2014.196. Epub 2014 Apr 10.

31.

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer.

Allevi G, Strina C, Andreis D, Zanoni V, Bazzola L, Bonardi S, Foroni C, Milani M, Cappelletti MR, Gussago F, Aguggini S, Giardini R, Martinotti M, Fox SB, Harris AL, Bottini A, Berruti A, Generali D.

Br J Cancer. 2013 Apr 30;108(8):1587-92. doi: 10.1038/bjc.2013.151. Epub 2013 Apr 11.

Supplemental Content

Loading ...
Support Center